Key Points for Decision Makers {#FPar1}
==============================

Lymph node (LN) staging is based on conventional gold-standard pathology, which analyses  \< 1% of the LN.LN micrometastases may not be detected by haematoxylin and eosin due to tumour allocation bias, and may cause tumour recurrences.A more accurate LN staging using the one-step nucleic acid amplification molecular assay could allow a better patient management, and only patients at risk of recurrence would be treated. Savings per patient in unneeded procedures and chemotherapy treatments stretch over the years, and may represent an important economic benefit for the National Health Service.

Introduction {#Sec1}
============

Colorectal cancer (CRC) is the third most common cancer worldwide, with nearly 1.8 million newly diagnosed cases in 2018, according to Globocan 2018 estimates \[[@CR1]\]. In Spain, CRC was the most prevalent type of cancer in 2017, with 34,331 new cases diagnosed that year, and was the second leading cause of death by cancer in 2016 \[[@CR2]\]. Over the last 30 years, improvements in early diagnosis and treatment have doubled the 5-year survival of CRC patients \[[@CR3]--[@CR6]\]; however, these improved outcomes have been costly and imposed a higher economic burden on health systems \[[@CR7]\]. In 2016, the mean cost per CRC patient in Spain ranged from €9634 among in situ tumours to €41,550 for stage III patients. Over this same period, the global mean cost per patient was €28,741 \[[@CR7]\].

Unless there are other factors that hinder the surgical procedure, surgical excision is the main approach for non-disseminated CRC \[[@CR8]\]. The presence of lymph node (LN) metastasis is a critical prognostic factor for patients with CRC, and also determines the need for adjuvant chemotherapy treatment \[[@CR9]\]. Pathological LN staging is considered the gold standard (GS), based on the evaluation of routine haemotoxylin and eosin (H&E)-stained slides; however, evidence indicates that it is not the best methodology of LN staging \[[@CR10]--[@CR13]\]. Significant limitations of this technique are its low sensitivity, since only a small part of the LN is examined \[[@CR10], [@CR14]--[@CR18]\], and the fact that it is a morphology-based analysis \[[@CR19]\]. The American Joint Committee on Cancer established that at least 12 LNs should be analysed to assure a reliable pathologic pN0 assessment \[[@CR20]\]. Therefore, undetected metastases within the unsampled material may be the cause of an increased risk of local recurrence and/or distant metastases after curative-intent surgery \[[@CR19]\]. Yamamoto et al. reported that 6 of 83 OSNA-positive LNs were diagnosed as negative by H&E and immunohistochemical staining (7.2%) \[[@CR9]\]. Other studies report that local recurrence or distant metastases occur in between 10 and 30% of CRC patients after surgical tumour resection \[[@CR6], [@CR14], [@CR16], [@CR18]\]. Moreover, stage II CRC patients with occult LN metastasis are considered a high-risk group for disease recurrence \[[@CR15]\], and between 10 and 25% of these patients die from disease \[[@CR6], [@CR21]\]. Therefore, missed LN metastases with the GS method might cause disease understaging, leading to the undertreatment of patients \[[@CR19]\].

An innovative technique called one-step nucleic acid amplification assay (OSNA) has been introduced in some hospitals in Europe and within the Asia-Pacific region for detecting LN metastases in patients with breast cancer. OSNA is a quantitative in vitro diagnostic molecular assay system, designed to measure the amount of tumoural cytokeratin 19 (CK19) messenger RNA (mRNA) within LNs \[[@CR9], [@CR22]\]. With OSNA, the LN total tumour burden or total tumour load is defined as the sum of all CK19 mRNA copies present in all dissected LNs of a given case \[[@CR15], [@CR23]\]. The total tumour load has already been implemented in routine clinical practice for breast cancer patients, allowing patients to be classified into low- and high-risk groups, independently of the pathologic pN stage and other prognostic factors. In breast cancer, the total tumour load has become a predictive factor for progression. It is related to patient outcome and has become a tool for patient management and decision making \[[@CR24]\].

One of the innovative aspects of OSNA is that, unlike the GS technique, OSNA can analyse the whole LN in a short time frame, and in an automatic and standardised way \[[@CR22]\]. OSNA is already being used for intraoperative sentinel LN diagnosis in breast carcinoma \[[@CR23]\], and has been demonstrated to be a time-efficient tool with standardised assessment of LNs \[[@CR19]\]. A CRC meta-analysis including five studies compared the cut-off point of OSNA versus the GS and demonstrated an average sensitivity of 89.4% and specificity of 93.3% \[[@CR19]\]. In addition, the OSNA assay is faster than the GS technique; OSNA takes 30--40 min to analyse all LNs from two patients, compared with the several hours required for GS analysis \[[@CR18]\].

In breast cancer, Saruta and Puig-Junoy estimated savings of US\$346 per patient over a 5-year period when OSNA was used intraoperatively instead of conventional intraoperative sentinel LN biopsy \[[@CR25]\]. The National Institute for Health and Care Excellence (NICE) assessed OSNA for CRC staging and estimated an average cost per patient (including capital, maintenance, and disposable costs) of between £568 and £608 (excluding value-added tax), depending on the cost of disposables (re-agents and consumables) \[[@CR22]\]. Nevertheless, budget impact studies of OSNA for CRC staging are lacking, highlighting the need for economic evaluations assessing OSNA in this patient population. The present study performed a budget impact analysis of OSNA in CRC patients in Spain, comparing two scenarios---GS and OSNA.

Materials and Methods {#Sec2}
=====================

Perspective and Time Horizon {#Sec3}
----------------------------

A 'what-if' budget impact analysis of introducing OSNA to perform LN analysis in CRC patients in the Spanish National Health System (NHS) was developed using the SensIt program (a sensitivity analysis add-in for Microsoft^®^ Excel 2007--2013 \[Microsoft Corporation, Redmond, WA, USA\]). The analysis was performed from the NHS perspective. Costs were calculated annually, corresponding to the number of patients newly diagnosed with CRC undergoing surgery during the first year, over a 3-year time horizon from 2017 to 2019. As recommended in budget impact analyses by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) \[[@CR26]\] and by a Spanish pharmacoeconomic guideline \[[@CR27]\], costs were not discounted. This analysis follows the ISPOR principles of Good Practice Framework \[[@CR26]\].

Features of the Spanish Health Care System {#Sec4}
------------------------------------------

The Spanish NHS is a decentralised system covering 17 Spanish regions \[[@CR28]\]. Medical procedures, tests and drugs administered in the hospital setting are totally covered by the Spanish health services. In Spain, medical devices are normally acquired by tendering procedures.

Eligible Population {#Sec5}
-------------------

The cohort of patients included in the present analysis comprised Spanish patients diagnosed with CRC who underwent curative-intent surgical excision. Inclusion criteria were patients over 18 years of age with primary histologically confirmed colon carcinoma and positive CK19 immunohistochemistry. Exclusion criteria were based mainly on technical reasons, i.e., open colectomies were excluded due to the risk of CK19 contamination from normal mucosa to LNs that did not contain CK19. Surgical specimens that were fixed in formalin were also excluded since the OSNA assay must be performed on fresh tissue. Rectal tumours treated with neoadjuvant therapy were excluded for the intrinsic difficulty of LN dissection after therapy. Cases with extensive fat infiltration were excluded since LNs cannot be identified and dissected in the middle of primary infiltrating tumour. The analysis was performed based on the estimated patient subgroups according to the recruitment performed by Rakislova et al. regarding systemic therapy (ST) administration \[[@CR18]\].

The patient cohort included in the study was obtained from Globocan data (34,331 estimated new cases of CRC in Spain) \[[@CR29]\], taking into account that 70.7% of patients diagnosed with CRC will undergo surgery, as reported by Corral et al. \[[@CR7]\]. In our study, the target population was further reduced, and only 74.1% of surgically treated patients could be included for LN OSNA analysis once the exclusion criteria detailed above were applied. The size of the target population was assumed to be constant over the 3-year time horizon.

Interventions {#Sec6}
-------------

Clinical schemes used to populate the model follow CRC National Comprehensive Cancer Network (NCCN) guidelines \[[@CR20]\], which are in line with Spanish clinical practice (Fig. [1](#Fig1){ref-type="fig"}). The treatment of choice for stage 0, I, II, or III CRC patients is surgical excision. After surgery, depending on tumour (pT) and LN status (pN) stage, some patients were treated with ST, consisting of different chemotherapy (QT) regimens \[[@CR30]--[@CR37]\]. LN analysis performed using the GS technique implies a risk of misdiagnoses, leading to undertreatment. Undertreated patients may have a higher risk for disease recurrence. According to guidelines, patients showing CRC recurrence might be treated with ST and/or surgery. ST after recurrence consists of QT regimens, which can include biological agents. The OSNA assay detection starts at 250 copies/µL, below 250 copies it is considered negative, allowing the selection of those patients who will very unlikely have tumoural cells in their LNs. However, the OSNA values and the clinical significance do not exactly correlate, and the presence of OSNA positivity does not imply a negative biological effect or patient recurrence by itself. A cut-off of 7500 copies/µL has been found to be related to a higher risk of recurrence and worse prognosis \[[@CR19], [@CR38]\]. Therefore, the threshold used in this study was 7500 copies/µL; OSNA values ≥ 7500/µL should be considered a positive result.Fig. 1Budget impact scenarios. *CEA* carcinoembryonic antigen, *CT* computed tomography, *€* Euros, *GS* gold standard, *OSNA* one-step nucleic acid amplification assay, *ST* systemic therapy

Scenarios and Model Description {#Sec7}
-------------------------------

The model compares a reference scenario versus a test scenario over a 3-year time horizon. The reference scenario assesses the management cost of CRC patients whose LNs have been analysed using the GS technique (H&E staining), while the test scenario estimates the management cost of CRC patients if LN analysis had been performed using the OSNA technique in the Spanish NHS framework (Fig. [1](#Fig1){ref-type="fig"}). Incident patients diagnosed during the first year of the analysis would be followed over the 3-year time horizon in order to collect costs associated with CRC disease.

The proportion of patients with positive or negative LNs, and the proportion of patients receiving ST after a positive or negative LN analysis, differs between scenarios (Fig. [1](#Fig1){ref-type="fig"}). In the reference scenario, 78.79% of patients showed negative LNs using the GS technique \[[@CR18]\], of which 15.99% were treated with ST according to data obtained from three different studies \[[@CR39]--[@CR41]\]. Some negative LN patients were treated based on decisions taken on multidisciplinary committees or recommendations made by clinical guidelines such as the NCCN.

In the reference scenario, 77.32% of patients with positive LNs by GS received ST \[[@CR39], [@CR41]\]. The model assumes that all patients with negative LNs analysed using the OSNA technique (86.47%) would not receive ST, while 77.32% of patients with a positive OSNA result (cut-off of \> 7500 copies/µL; 13.53%) would be treated with ST. Patients with no ST would enter the follow-up period after surgery, while patients receiving ST would enter the follow-up period after adjuvant treatment. During the first year of follow-up, 98.10% and 98.82% of patients in the reference and test scenarios, underwent and would undergo, respectively, colonoscopies, medical visits, blood tests (including monitoring of carcinoembryonic antigen; CEA) and computed tomography (CT) scans. The proportion of patients using the latter healthcare resources in the reference and test scenarios would be 96.21% and 97.64%, respectively, during the second year, and 92.42% and 95.29%, respectively, during the third year. The frequency of tests and visits is described in Table [1](#Tab1){ref-type="table"}.Table 1Inputs used for the base-case and sensitivity analysesParametersInputsReferencesRange (lowest--highest)CRC incidence (*N*)34,331\[[@CR54]\]10--521,490Lymph node (*N*)15.00\[[@CR55]\]10.00--27.00GS**-**negative (%)78.79\[[@CR9], [@CR18], [@CR39]\]66.14--100GS**-**positive (%)21.21\[[@CR9], [@CR16], [@CR18]\]0.00--33.89GS**-**negative, no ST (%)84.01\[[@CR39]--[@CR41]\]79.69--100GS**-**negative, ST (%)15.99\[[@CR9], [@CR39], [@CR40]\]12.20--20.30GS**-**positive, ST (%)77.32\[[@CR9], [@CR39]\]62.64--92.00OSNA**-**negative (%)86.47\[[@CR16], [@CR18]\]61.27--100OSNA**-**positive (%)13.53\[[@CR16], [@CR18]\]0.00--33.85OSNA**-**negative, no ST (%)100.00\[[@CR20]\]79.69--100.00OSNA**-**positive, ST (%)77.32\[[@CR39], [@CR40]\]62.64--92.00Recurrence GS**-**negative (%)1.92\[[@CR18], [@CR56]\]0.00--1.92Recurrence GS**-**positive (%)28.57\[[@CR18], [@CR56]\]0.00--28.57ST for recurrence GS (%)83.73\[[@CR40]\]0.00--100.00Surgery for recurrence GS (%)42.68\[[@CR40]\]0.00--100.00Recurrence OSNA**-**negative (%)1.36\[[@CR18], [@CR56]\]0.00--1.36Recurrence OSNA**-**positive (%)26.09\[[@CR18], [@CR56]\]0.00--26.09ST for recurrence OSNA (%)83.73\[[@CR40]\]0.00--100.00Surgery for recurrence OSNA (%)42.68\[[@CR40]\]0.00--100.00Recurrence GS (%)^a^3.79\[[@CR18]\]0.00--7.58Recurrence OSNA (%)^a^2.36\[[@CR18]\]0.00--4.71Hospitalisation days (*N*)7.00\[[@CR57]\]1--14Blood test, CEA, visits (*N*)4.00\[[@CR20]\]2.00--8.00Abdominal CT (*N*)1.00\[[@CR20]\]1.00--3.00Thoracoabdominal CT (*N*)1.00\[[@CR20]\]0.00--2.00Colonoscopy (*N*)1.00\[[@CR20]\]0.00--2.00Surgery after diagnosis (€)2804.00\[[@CR44]\]1402.00--5608.00GS (cost per lymph node; €)10.00\[[@CR44]\]5.00--20.00OSNA (cost per patient; €)500.00\[[@CR58]\]^b^250--700Hospitalisation daily cost (€)347.00\[[@CR44]\]112.00--582.00ST after first surgery (€)2293.66\[[@CR20], [@CR42], [@CR43], [@CR56], [@CR59]--[@CR65]\]687.91--3739.75Colonoscopy (€)235.51\[[@CR44]\]120.00--285.00CEA (€)29.00\[[@CR44]\]20.00--38.00Blood test (€)99.19\[[@CR44]\]46.78--184.89Thoracoabdominal (€)134.33\[[@CR44]\]73.00--165.00Abdominal CT (€)135.00\[[@CR44]\]62.00--168.00Medical visit (€)26.57\[[@CR44]\]21.60--29.88ST after recurrence (€)21,966.71\[[@CR20], [@CR42], [@CR43], [@CR59]--[@CR73]\]687.91--32,538.31Surgery for recurrence (€)5937.00\[[@CR44]\]5038.00--7252.00*CEA* carcinoembryonic antigen, *CRC* colorectal cancer, *CT* computed tomography, *GS* gold standard, *N* number of patients, *OSNA* one-step nucleic acid amplification assay, *ST* systemic therapy, *€* Euros^a^Refers to the overall recurrence rate during the first year in both scenarios, independently of the results obtained^b^Data provided by the manufacturer

The percentage of patients with recurrence was obtained from a recently published study comparing GS and OSNA over a 2-year period \[[@CR18]\]. Recurrence rates observed by Rakislova et al. \[[@CR18]\] during the 2-year period are assumed to be maintained during the third year of the analysis for both the GS and OSNA techniques. In both scenarios, 42.68% of recurrent patients underwent surgery for recurrence and 83.73% received ST for recurrence each year of the analysis \[[@CR40]\].

Input Data {#Sec8}
----------

Assumed parameter values for all clinical and cost data for both scenarios are shown in Table [1](#Tab1){ref-type="table"}, and the strengths, weaknesses and potential data biases are described in electronic supplementary Table S1. We conducted a search of the Pubmed and eSalud electronic databases using different combinations of keywords, such as 'OSNA', 'colorectal cancer', 'National Health System' and 'costs'. Data credibility was assessed as described in the data extraction protocol (electronic supplementary Table S2).

Costs {#Sec9}
-----

The present analysis only includes direct costs from 2017, with all costs given in Euros (€). Drug costs were calculated based on the ex-factory price (PVL, Spanish acronym for Precio de Venta del Laboratorio) \[[@CR42]\]. Daily defined doses were obtained from the summary of product characteristics of each drug, and from clinical trials if not specified in the summary of product characteristics. The daily dose per patient was calculated considering an average weight and height of 70.2 kg and 166 cm, respectively \[[@CR43]\]. Regarding drugs administered intravenously, vial wastage was assumed. The cost of ST following first surgery is the average cost of the common QT regimens used in clinical practice, and the cost of ST after recurrence is an average value of the cost of the QT regimens and biological agents (Table [2](#Tab2){ref-type="table"}). An outlier detection technique was used when calculating the average cost of ST, excluding those QT regimens with an annual cost under the average cost divided by two. The cost of other health resources used, such as medical visits and tests, were obtained from the Spanish health costs database \[[@CR44]\].Table 2Systemic treatments considered following the first surgery and after recurrenceMoleculeDose per cycleNo. of cycles per yearCost per cycle (€)Annual cost (€)*ST following first surgery; clinical data sources*Capecitabine \[[@CR37]\]Capecitabine35,000 mg/m^2^8116.13929.04CAPOX^a^ \[[@CR31], [@CR35], [@CR36]\]Capecitabine28,000 mg/m^2^4410.801643.22Oxaliplatin130 mg/m^2^CAPOX^a^ \[[@CR31], [@CR35], [@CR36]\]Capecitabine28,000 mg/m^2^8410.803286.43Oxaliplatin130 mg/m^2^Fluorouracil/leucovorin (bimonthly) \[[@CR30], [@CR32]--[@CR34], [@CR60]\]Fluorouracil400 mg/m^2^1257.33687.91Fluorouracil1200 mg/m^2^Leucovorin200 mg/m^2^FOLFOX4^b^ \[[@CR30], [@CR31], [@CR35], [@CR36], [@CR60]\]Oxaliplatin85 mg/m^2^6311.651869.87Leucovorin200 mg/m^2^Fluorouracil400 mg/m^2^Fluorouracil2400 mg/m^2^FOLFOX4^b^ \[[@CR30], [@CR31], [@CR35], [@CR36], [@CR60]\]Oxaliplatin85 mg/m^2^12311.653739.75Leucovorin200 mg/m^2^Fluorouracil400 mg/m^2^Fluorouracil2400 mg/m^2^*ST for recurrence; clinical data sources*Bevacizumab/CAPOX \[[@CR69], [@CR74]\]Bevacizumab7.5 mg/kg121733.6020,803.25CAPOX^a^Bevacizumab/FOLFOX6 \[[@CR69]\]Bevacizumab5 mg/kg121634.4519,613.35FOLFOX6^b^Bevacizumab/FOLFIRI \[[@CR68]--[@CR70]\]Bevacizumab5 mg/kg121453.4017,440.75Irinotecan360 mg/m^2^Leucovorin800 mg/m^2^Fluorouracil400 mg/m^2^Fluorouracil4800 mg/m^2^Bevacizumab/FOLFOXIRI \[[@CR68]\]Bevacizumab5 mg/kg121682.0220,184.27Irinotecan165 mg/m^2^Oxaliplatin85 mg/m^2^Leucovorin200 mg/m^2^Fluorouracil3200 mg/m^2^Cetuximab/FOLFOX6 \[[@CR69]\]Cetuximab500 mg/m^2^122111.5625,338.67FOLFOX6^b^Cetuximab/FOLFOX6 \[[@CR69]\]Cetuximab650 mg/m^2^122711.5332,538.31FOLFOX6^b^Cetuximab/FOLFIRI \[[@CR69]\]Cetuximab500 mg/kg121930.5123,166.07Irinotecan180 mg/m^2^Leucovorin400 mg/m^2^Fluorouracil400 mg/m^2^Fluorouracil2400 mg/m^2^Cetuximab/FOLFIRI \[[@CR69]\]Cetuximab400 mg/m^2^122530.5130,365.71Irinotecan180 mg/m^2^Leucovorin400 mg/m^2^Fluorouracil400 mg/m^2^Fluorouracil2400 mg/m^2^Panitumumab/FOLFIRI \[[@CR75]\]Panitumumab6 mg/kg121958.9523,507.35Irinotecan180 mg/m^2^Leucovorin400 mg/m^2^Fluorouracil400 mg/m^2^Fluorouracil2400 mg/m^2^Panitumumab/FOLFOX6 \[[@CR72]\]Panitumumab6 mg/kg122140.0025,679.95FOLFOX6^b^*ST* systemic therapy, *€* Euros^a^Treatment regimen includes the same molecules and doses per cycle indicated for CAPOX^b^Treatment regimen includes the same molecules and doses per cycle indicated for FOLFOX4

Sensitivity Analyses {#Sec10}
--------------------

A one-way sensitivity analysis (OWSA) was performed in order to assess the uncertainty and robustness of the model. Clinical and cost parameters were increased and decreased according to the minimum and maximum values shown in Table [1](#Tab1){ref-type="table"}, which were mostly obtained from the literature. For the purposes of sensitivity analyses, the lowest (Vanuatu) and highest (China) number of possible incident patients worldwide was considered \[[@CR29]\].

In addition, a two-way sensitivity analysis (TWSA) was performed to further assess the uncertainty regarding those clinical parameters that were correlated and should be simultaneously varied; varying them independently may show misleading results: 'positivity of GS vs. OSNA', 'recurrence in follow-up: GS vs. OSNA', 'recurrence in ST: GS vs. OSNA' and 'ST after recurrence with GS vs. OSNA'.

Results {#Sec11}
=======

Target Population {#Sec12}
-----------------

The number of patients diagnosed with CRC who underwent surgery was estimated as 24,265 per year, of which 17,980 would be eligible for OSNA. In the reference scenario, 5214 patients would receive ST after surgery, whereas in the test scenario, only OSNA-positive patients (1615) would receive ST after surgery. More patients in the reference scenario (1362) recurred than in the test scenario (727), and, after recurrence, fewer patients in the test scenario would undergo surgery (310 vs. 581) and receive ST compared with the reference scenario (608 vs. 1140).

Budget Impact After the Introduction of the One-Step Nucleic Amplification Technique {#Sec13}
------------------------------------------------------------------------------------

The overall cost of the reference scenario for the first, second and third years was estimated at €182,711,803, €52,101,734 and €62,878,813, respectively, while in the test scenario, the overall cost for the first, second and third years was €181,202,621, €45,247,233 and €52,064,732, respectively. From these results, the corresponding savings were estimated to be €1,509,182 in year 1, €6,854,501 in year 2, and €10,814,082 in year 3, corresponding to savings of 0.002%, 0.010% and 0.016% in the Spanish public health expenditure in 2014 (€66,826 million) \[[@CR45]\]. Therefore, the introduction of OSNA in Spanish clinical practice for performing LN analysis from CRC surgical specimens could lead to an overall cost saving of €19,177,765 for the Spanish NHS over a 3-year time horizon (Table [3](#Tab3){ref-type="table"}).Table 3Results of the budget impact of introducing OSNA in Spanish clinical practice over a 3-year time horizon (Euros)Year 1Year 2Year 3Reference scenario (GS)Test scenario (OSNA)Reference scenario(GS)Test scenario (OSNA)Reference scenario (GS)Test scenario (OSNA)Surgery126,983,355126,983,3550.000.000.000.00Staging2,697,0728,990,2400.000.000.000.00ST after first surgery11,959,1354,314,3960.000.000.000.00Follow-up33,114,22133,355,56131,856,88932,565,72030,628,24931,789,382Recurrence surgery1,691,0661,606,2891,658,9401,040,5191,626,8141,028,025ST after recurrence6,266,9555,952,78118,585,90511,640,99430,623,75019,247,325Total cost182,711,803181,202,62152,101,73445,247,23362,878,81352,064,732Budget impact1,509,1826,854,50110,814,082*GS* gold standard, *OSNA* one-step nucleic acid amplification assay, *ST* systemic therapy

The overall cost per patient using the GS or OSNA techniques is estimated to be €13,193 and €12,126, respectively. Therefore, cost savings of €1067 per patient for the next 3 years after CRC diagnosis are achievable if the OSNA technique replaced the GS technique in the Spanish NHS.

Sensitivity Analyses {#Sec14}
--------------------

Results obtained from the OWSA and TWSA show the robustness of the analysis performed and confirm the results obtained (Figs. [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}, respectively). The parameters with a higher impact on the results are those relating to the proportion of patients with negative results, using both the GS and OSNA techniques, and the treatment cost after diagnosis and recurrence. The results obtained by reducing and increasing the parameters included in the analysis are in line with the base-case results, therefore generating savings for the Spanish NHS if OSNA was introduced in clinical practice (Fig. [2](#Fig2){ref-type="fig"}). Figure [3](#Fig3){ref-type="fig"} shows that in each of the four analyses, the base case is located within the area under the line, where savings for the NHS would be expected. Lines drawn in Fig. [3](#Fig3){ref-type="fig"} show simultaneous variations of the two parameters included in each analysis.Fig. 2Tornado diagram, one-way sensitivity analysis results. Vertical line indicates the total cost saving from the base case, and the horizontal lines indicate the shift in the range of outputs obtained by varying each input to a lower (black) and higher (light grey) value. *CEA* carcinoembryonic antigen, *CT* computed tomography, *GS* gold standard, *N* number of patients, *OSNA* one-step nucleic acid amplification assay, *ST* systemic therapy, *€* EurosFig. 3Two-way sensitivity analysis results. *GS* gold standard, *OSNA* one-step nucleic acid amplification assay, *ST* systemic therapy

Discussion {#Sec15}
==========

This study focuses on a novel way of assessing the economic impact of the use of OSNA instead of the traditional GS technique for CRC patients in Spain. Our results indicate that the Spanish NHS would have saved over €19 million from 2017 to 2019 if OSNA had been introduced in clinical practice for surgically treated CRC patients. Savings are explained by the fact that OSNA ensures a more accurate diagnosis in CRC patients, allowing a reduction in treatment costs after initial surgery, as well as costs of adjuvant treatments and surgery after recurrence, compared with GS techniques. Although patients' LN staging is more expensive with OSNA than with GS, savings regarding treatment costs after surgery and treatment costs due to recurrence are high enough to make a return on the investment made by the incorporation of OSNA at the diagnostic stage. Savings have already been observed during the first year, and increase during the second and third years of the analysis. Sensitivity analyses showed the robustness of the analysis. The number of incident patients is the variable showing a higher impact on the result in the OWSA (the higher the patient population, the greater the savings for the NHS). According to Globocan data \[[@CR29]\], the countries reporting the lowest and highest crude incidence rate for CRC are Gambia and Japan, respectively. If these incidence rates were applied to the Spanish population, the number of incidence cases per year would be approximately between 238 and 54,404.

A previous study performed with breast cancer patients in Japan over a 5-year time horizon showed that the use of OSNA would lead to relevant Japanese healthcare savings of approximately US\$121,877,910 \[[@CR25]\]. In addition to the difference of diagnosis, treatment and follow-up, the influence of pathological nodal staging on treatment decision in breast cancer and CRC is different. In CRC, the aim is to pursue those cases at risk of recurrence, while in breast carcinoma, a surgical decision of performing lymphadenectomy is undertaken, which does not depend on pathological nodal staging. Therefore, these results do not directly relate/correspond to those obtained in the present study.

Several authors agree on using more sensitive molecular methods of LN staging in CRC, rather than GS \[[@CR11], [@CR12], [@CR46]--[@CR49]\], to help identify CRC patients who are histologically LN-negative after a potentially curative surgical resection and who are nevertheless at risk of recurrence \[[@CR12], [@CR47], [@CR48]\]. Precise pathological LN staging is critical in determining the most suitable treatment \[[@CR50], [@CR51]\]. Nevertheless, not only are new techniques needed to achieve better patient staging but also new treatments with improved outcomes, as efficacy observed with current chemotherapy regimens for CRC is limited \[[@CR52]\].

The results of the present study relate to Spain, however the OSNA technique could also be incorporated in other countries. Further studies comparing clinical outcomes such as recurrence rates or overall survival between patients whose LNs have been analysed using the OSNA technique versus the GS technique would be of interest. Moreover, although this study reports a relevant economic benefit for the Spanish NHS in a scenario using OSNA, further pharmacoeconomic evaluations, such as cost-effectiveness analysis, could also help health services make informed decisions regarding the feasibility of introducing OSNA in their clinical practice.

Limitations {#Sec16}
-----------

Pharmacoeconomic studies are subject to limitations, mainly due to the fact that reality ought to be simplified in order to elaborate the model. The present analysis assumed that the size of the target population remained unchanged over the 3-year period in order to collect all costs associated with the incident cohort. At the time of the study, no data were available regarding the mortality rates compared between OSNA and GS. Furthermore, clinical data used to calculate the proportion of patients with negative and positive results in the reference and test scenarios were taken from different studies including a sample of patients, which might differ from real clinical practice in Spain. However, inputs regarding the staging and recurrence rates of patients were obtained from the same study for consistency. Additionally, the proportion of negative and positive OSNA results might be associated with sample bias in the study design, which was performed according to the actual guidelines of LN analysis and staging in CRC. To date, all CRC studies performed using OSNA have the same sample bias, resulting from using part of the LNs for H&E analysis and GS staging, and using the rest for OSNA. Consequently, metastasis might have only been present in part of the H&E analysis, leading to false negative OSNA results \[[@CR17], [@CR18], [@CR53]\].

Furthermore, another limitation is in regard to data obtained from Rakislova et al. \[[@CR18]\], as LNs were analysed using both the GS and OSNA techniques, and treated according to the GS diagnosis. Therefore, patient outcomes remain unknown in the hypothetical case that patients' treatment decisions would have only been based on the OSNA results. Hence, a randomised study is needed to obtain accurate outcomes in those patients treated after the OSNA results had been reported and those treated after GS diagnosis, in order to assess a possible differential treatment effect depending on the staging diagnostic procedure performed, i.e., OSNA or GS. Costs related to adverse effects and adverse events management were not included in both interventions since they are the same for both OSNA and GS. Diagnosis is performed after tissue containing the tumour is resected from the patient. Therefore, patients do not undergo extra interventions as LN analysis is performed in the laboratory, with no adverse events for the patient. Thus, adverse events relating to diagnostic techniques for CRC have not been identified.

Conclusions {#Sec17}
===========

The introduction of OSNA for the management of CRC patients in Spanish clinical practice may represent an economic benefit for the NHS, as well as clinical benefit for CRC patients. OSNA results offer higher diagnostic reliability than the currently used GS techniques. The introduction of OSNA may allow more accurate staging of patients, which could help in avoiding unnecessary treatments without affecting a patient's prognosis (recurrence), or may provide the opportunity to receive treatment for those patients who could really benefit from it.
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 {#Sec18}
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